Conserv:
Contrail Capital invested in the company in 2024 and will assist the company with its European expansion.
Scantrust:
Contrail Capital invested in the company in 2024 and will support the company’s expansion in the United States.
Matis:
Contrail Capital invested in the company in 2024 and will support the company’s expansion in the United States and Europe.
Aceandcompany:
Contrail Capital invested in the company in 2024 and will assist the company with its European expansion.
Nezasa:
Contrail Capital invested in the company in 2024 and will support the company’s expansion in the United States and Europe.
Positrigo:
With CE marking in Europe and FDA clearance in the US, NeuroLF is a breakthrough in neurological diagnostics, addressing conditions such as Alzheimer’s, epilepsy, and brain tumors. Recognized with the iF DESIGN AWARD 2025, Positrigo combines innovation and precision engineering to make advanced brain imaging accessible and practical for clinical use worldwide.
Contrail Capital invested in the company in April 2025 and will support the company’s expansion in the United States and Europe.
Smeetz:
Contrail Capital invested in the company in June 2025 and will support the company’s expansion in the United States and Europe.
Iyris:
The company collaborates with growers, research institutions, and technology partners worldwide to deliver tailored solutions that enhance agricultural productivity and sustainability.
Contrail Capital invested in Iyris in 2025 and will support its expansion in the United States and Europe.